The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP245...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: O'Hare, Thomas, Zabriskie, Matthew S., Eide, Christopher A., Agarwal, Anupriya, Adrian, Lauren T., You, Huihong, Corbin, Amie S., Yang, Fei, Press, Richard D., Rivera, Victor M., Toplin, Julie, Wong, Stephane, Deininger, Michael W., Druker, Brian J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2011
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3217407/
https://ncbi.nlm.nih.gov/pubmed/21908430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-05-349191
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi